HMGBiotech is a biotech company that provides reagents, services and ideas to researchers and companies active in the HMGB field.
The only producer of quality-controlled redox variants of HMGB1
High Mobility Group Box 1 (HMGB1), also known as HMG-1 or amphoterin, is a highly conserved nuclear protein encoded by the HMGB1 gene. As a member of the high mobility group family, HMGB1 contains a characteristic HMG-box domain, which enables its interaction with DNA and other nuclear components.
Featured news
A recent study has revealed that HMGB1 dimerization is a key player in immune signaling. When two HMGB1 molecules join through a Cys106–Cys106 disulfide bond, their #inflammatory potential intensifies.
Two recent studies shed light on how HMGB1 contributes to Kaposi’s sarcoma (KS) and small cell lung cancer (SCLC), revealing new potential therapeutic strategies for cancer.
HMGB1 (High Mobility Group Box 1) isoforms can be used to explore the mechanisms of several disease models.
All proteins are LPS free, so they are suitable for in vitro and in vivo researches.
Fully reduced HMGB1
All the three cysteines are completely reduced. HMGB1 acts as potent chemoattractant for many cells type. Read more…
Disulfide HMGB1
If two cysteines have a disulfide bond. HMGB1 acts as proinflammatory mediator. Read more…
Terminally oxidized HMGB1
The three cysteines are oxidized to sulfonate. HMGB1 is inactive. Read more…
From our LinkedIn profile
Featured Products
About us
HMGBiotech has R&D and production unit within Ospedale San Raffaele, one of the leading research institutes in Italy as per volume and quality of scientific output. Read more about our company…
